Orionis Biosciences
Delaware LLC · 5 known investors
Orions Bio discovers, designs and engineers molecules that connect proteins on and within cells to reprogram disease-driving processes or activate immune responses. The company develops small molecule drugs, conditionally active cytokines, and multimodal cell engagers for cancer, autoimmune diseases, and neurodegenerative disorders.
Founders & leadership
GV
Griet Vanpoucke, Ph.D.Director
SR
Steven R. Gullans, Ph.D.Director
NK
Nikolai Kley, Ph.D.Executive Officer, Director
Investors · 5
Reported raises · per SEC filings
Form D private placements▶$19.7MraisedApr 2018 · 9 investors · BiotechnologyRule 506(b)
▶$19.7MraisedApr 2018 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Griet Vanpoucke, Ph.D.Director
- Nikolai Kley, Ph.D.Executive Officer, Director
- Steven R. Gullans, Ph.D.Director
- Offering amount
- $25.5M
- Amount sold
- $19.7M
- First sale
- Mar 2018
- Incorporated
- Limited Liability Company, Delaware, 2015
- Federal exemptions
- 06b
▶$750KraisedJan 2017 · 1 investors · BiotechnologyRule 506(b)
▶$750KraisedJan 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nikolai Kley, Ph.D.Executive Officer, Director
- Griet Vanpoucke, Ph.D.Director
- Steven R. Gullans, Ph.D.Director
- Offering amount
- $5.3M
- Amount sold
- $750K
- First sale
- Jan 2017
- Incorporated
- Limited Liability Company, Delaware, 2015
- Federal exemptions
- 06b
▶$4MraisedOct 2015 · 4 investors · BiotechnologyRule 506(b)
▶$4MraisedOct 2015 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Griet Vanpoucke, Ph.D.Director
- Steven R. Gullans, Ph.D.Director
- Nikolai Kley, Ph.D.Executive Officer, Director
- Offering amount
- $5.3M
- Amount sold
- $4M
- First sale
- Sep 2015
- Incorporated
- Limited Liability Company, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.